Altimmune, Inc. (ALT)
2025-03-31 | 2024-09-30 | |||
|---|---|---|---|---|
| Revenues | 5 | 5 | ||
| Research and development | 15,827 | 19,803 | ||
| General and administrative | 5,993 | 4,969 | ||
| Total operating expenses | 21,820 | 24,772 | ||
| Loss from operations | -21,815 | -24,767 | ||
| Other income (expense), net | 15 | 18 | ||
| Interest income | 1,545 | 1,910 | ||
| Interest expense | 1 | 6 | ||
| Total other income (expense), net | 1,559 | 1,922 | ||
| Net loss before income taxes | -20,256 | - | ||
| Income tax expense (benefit) | -681 | - | ||
| Net loss | -19,575 | -22,845 | ||
| Other comprehensive income - unrealized gain on short-term investments | -30 | 347 | ||
| Comprehensive loss | -19,605 | -22,498 | ||
| Basic eps | -0.26 | -0.32 | ||
| Diluted eps | -0.26 | -0.32 | ||
| Basic average shares | 75,547,746 | 71,084,787 | ||
| Diluted average shares | 75,547,746 | 71,084,787 | ||